Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

Cited In for PubMed (Select 18548070)

1.

Independent relationship between amyloid precursor protein (APP) dimerization and γ-secretase processivity.

Jung JI, Premraj S, Cruz PE, Ladd TB, Kwak Y, Koo EH, Felsenstein KM, Golde TE, Ran Y.

PLoS One. 2014 Oct 28;9(10):e111553. doi: 10.1371/journal.pone.0111553. eCollection 2014.

2.

A subset of membrane-altering agents and γ-secretase modulators provoke nonsubstrate cleavage by rhomboid proteases.

Urban S, Moin SM.

Cell Rep. 2014 Sep 11;8(5):1241-7. doi: 10.1016/j.celrep.2014.07.039. Epub 2014 Aug 21.

3.

Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.

Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P.

J Neuroinflammation. 2014 Jul 8;11:120. doi: 10.1186/1742-2094-11-120. Review.

4.

Discovery of a Potent Pyrazolopyridine Series of γ-Secretase Modulators.

Qin J, Zhou W, Huang X, Dhondi P, Palani A, Aslanian R, Zhu Z, Greenlee W, Cohen-Williams M, Jones N, Hyde L, Zhang L.

ACS Med Chem Lett. 2011 Mar 29;2(6):471-6. doi: 10.1021/ml2000438. eCollection 2011 Jun 9.

5.

FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.

Deng Q, Holler CJ, Taylor G, Hudson KF, Watkins W, Gearing M, Ito D, Murray ME, Dickson DW, Seyfried NT, Kukar T.

J Neurosci. 2014 Jun 4;34(23):7802-13. doi: 10.1523/JNEUROSCI.0172-14.2014.

6.

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.

Karran E, Hardy J.

Ann Neurol. 2014 Aug;76(2):185-205. doi: 10.1002/ana.24188. Epub 2014 Jul 2. Review. No abstract available.

7.

Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Uversky VN, Davé V, Iakoucheva LM, Malaney P, Metallo SJ, Pathak RR, Joerger AC.

Chem Rev. 2014 Jul 9;114(13):6844-79. doi: 10.1021/cr400713r. Epub 2014 May 15. Review. No abstract available.

8.

Pharmacological targeting of the β-amyloid precursor protein intracellular domain.

Branca C, Sarnico I, Ruotolo R, Lanzillotta A, Viscomi AR, Benarese M, Porrini V, Lorenzini L, Calzà L, Imbimbo BP, Ottonello S, Pizzi M.

Sci Rep. 2014 Apr 9;4:4618. doi: 10.1038/srep04618.

9.

Complex relationships between substrate sequence and sensitivity to alterations in γ-secretase processivity induced by γ-secretase modulators.

Jung JI, Ran Y, Cruz PE, Rosario AM, Ladd TB, Kukar TL, Koo EH, Felsenstein KM, Golde TE.

Biochemistry. 2014 Apr 1;53(12):1947-57. doi: 10.1021/bi401521t. Epub 2014 Mar 20.

10.

Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Cudaback E, Jorstad NL, Yang Y, Montine TJ, Keene CD.

Biochem Pharmacol. 2014 Apr 15;88(4):565-72. doi: 10.1016/j.bcp.2013.12.014. Epub 2014 Jan 13. Review.

11.

Binding of longer Aβ to transmembrane domain 1 of presenilin 1 impacts on Aβ42 generation.

Ohki Y, Shimada N, Tominaga A, Osawa S, Higo T, Yokoshima S, Fukuyama T, Tomita T, Iwatsubo T.

Mol Neurodegener. 2014 Jan 13;9:7. doi: 10.1186/1750-1326-9-7.

12.

Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species.

Wagner SL, Zhang C, Cheng S, Nguyen P, Zhang X, Rynearson KD, Wang R, Li Y, Sisodia SS, Mobley WC, Tanzi RE.

Biochemistry. 2014 Feb 4;53(4):702-13. doi: 10.1021/bi401537v. Epub 2014 Jan 22.

13.

APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based γ-secretase modulation.

Mertens J, Stüber K, Wunderlich P, Ladewig J, Kesavan JC, Vandenberghe R, Vandenbulcke M, van Damme P, Walter J, Brüstle O, Koch P.

Stem Cell Reports. 2013 Dec 5;1(6):491-8. doi: 10.1016/j.stemcr.2013.10.011. eCollection 2013.

14.

Characterization of intermediate steps in amyloid beta (Aβ) production under near-native conditions.

Olsson F, Schmidt S, Althoff V, Munter LM, Jin S, Rosqvist S, Lendahl U, Multhaup G, Lundkvist J.

J Biol Chem. 2014 Jan 17;289(3):1540-50. doi: 10.1074/jbc.M113.498246. Epub 2013 Nov 13.

15.

Toward the structure of presenilin/γ-secretase and presenilin homologs.

Wolfe MS.

Biochim Biophys Acta. 2013 Dec;1828(12):2886-97. doi: 10.1016/j.bbamem.2013.04.015. Review.

16.

Competition between homodimerization and cholesterol binding to the C99 domain of the amyloid precursor protein.

Song Y, Hustedt EJ, Brandon S, Sanders CR.

Biochemistry. 2013 Jul 30;52(30):5051-64. doi: 10.1021/bi400735x. Epub 2013 Jul 18.

17.

γ-Secretase inhibitors and modulators.

Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L.

Biochim Biophys Acta. 2013 Dec;1828(12):2898-907. doi: 10.1016/j.bbamem.2013.06.005. Epub 2013 Jun 17. Review.

18.

Steroids as γ-secretase modulators.

Jung JI, Ladd TB, Kukar T, Price AR, Moore BD, Koo EH, Golde TE, Felsenstein KM.

FASEB J. 2013 Sep;27(9):3775-85. doi: 10.1096/fj.12-225649. Epub 2013 May 28.

19.

Progranulin does not bind tumor necrosis factor (TNF) receptors and is not a direct regulator of TNF-dependent signaling or bioactivity in immune or neuronal cells.

Chen X, Chang J, Deng Q, Xu J, Nguyen TA, Martens LH, Cenik B, Taylor G, Hudson KF, Chung J, Yu K, Yu P, Herz J, Farese RV Jr, Kukar T, Tansey MG.

J Neurosci. 2013 May 22;33(21):9202-13. doi: 10.1523/JNEUROSCI.5336-12.2013.

20.

Target Identification by Diazirine Photo-Cross-linking and Click Chemistry.

Mackinnon AL, Taunton J.

Curr Protoc Chem Biol. 2009 Dec;1:55-73.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk